AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
29 févr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla.,...
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
27 févr. 2024 08h30 HE
|
Imunon, Inc.
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
15 févr. 2024 07h30 HE
|
Theratechnologies
Une étape importante de l’étude afin de poursuivre l’élan pour le principal CPM de la Société et son programme de développement clinique en oncologie MONTRÉAL, 15 févr. 2024 (GLOBE...
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
15 févr. 2024 07h30 HE
|
Theratechnologies
Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc....
Oncology Biomarkers Market Forecast to Reach $23 Billion by 2027 According to New Research Report
24 janv. 2024 13h27 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Oncology Biomarkers Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The recently published report on the...
BRCA Tests Market Regulatory, Reimbursement and Forecasts to 2033
09 janv. 2024 11h03 HE
|
Research and Markets
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering....
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11 déc. 2023 08h30 HE
|
Imunon, Inc.
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE...
Ovarian Cancer Drugs Market Size Worth USD 5.35 Billion in 2032 | Emergen Research
28 nov. 2023 11h00 HE
|
Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global ovarian cancer drugs market is set to experience substantial expansion, reaching a size of USD 2.40 Billion in 2022 and projecting an...
Monoclonal Antibodies Market Size Worth USD 572.62 Billion in 2032 | Emergen Research
28 nov. 2023 08h17 HE
|
Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast...
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
27 nov. 2023 07h00 HE
|
Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer